Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies

References

• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;252:207-74
   PubMed Web of Science ®Google Scholar
• Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011;377:557-67
   PubMed Web of Science ®Google Scholar
• Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011;378:31-40
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77
   PubMed Web of Science ®Google Scholar
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N Engl J Med 1995;333:1670-6
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators N Engl J Med 1995;332:80-5
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Weir MR Angiotensin-converting enzyme inhibitors. J Clin Hypertens 2011;13:667-75
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:2354-94
   PubMed Web of Science ®Google Scholar
• Fares H, DiNicolantonio JJ, O'Keefe JH, et al. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart 2016;3:e000473
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Bakris G, Briasoulis A, Dahlof B, et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol 2013;112:255-9
   PubMed Web of Science ®Google Scholar
• Stompór T, Napora M, Olszewski A. Renoprotective effects of benazepril: current perspective. Expert Rev Cardiovasc Ther 2011;9:663-73
   PubMedGoogle Scholar
• Mourad JJ. Which patients benefit the most from the perindopril/amlodipine combination. J Hypertens 2011;29(Suppl.1):S23-8
   PubMedGoogle Scholar
• Simonyi G. Benefits of fixed dose combination of ramipril/amlodipine in hypertensive diabetic patients: a subgroup analysis of RAMONA trial. Chin Med J (Engl) 2016;129:1224-8
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-Term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145:80-7
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E. Survival of Myocardial Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007;153:445
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E, Novo S, et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012;35:416-23
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
   PubMed Web of Science ®Google Scholar
• Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005;165:1192-8
   PubMedGoogle Scholar
• Kul S, Uyarel H, Gul M, et al. Metabolic syndrome and long-term cardiovascular outcomes in NSTEMI with unstable angina. Nutr Metab Cardiovasc Dis 2014;24:176-82
   PubMed Web of Science ®Google Scholar
• Yazici HU, Poyraz F, Turfan M, et al. The prevalence of the metabolic syndrome and its impact on the left ventricular systolic function in the patients with non-diabetic first ST elevation myocardial infarction. Eur Rev Med Pharmacol Sci 2012;16:90-5
   PubMed Web of Science ®Google Scholar
• Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag 2008;4:665-71
   PubMedGoogle Scholar
• Mason RP, Jacob RF, Corbalan JJ, et al. Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Am J Hypertens 2014;27:482-8
   PubMed Web of Science ®Google Scholar
• Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005;33:42-54
   PubMed Web of Science ®Google Scholar